Sickle cell disease begins with a tiny genetic change but can have enormous consequences.
The condition causes red blood cells to become rigid and misshapen. Those cells can obstruct blood flow, producing episodes of severe pain known as vaso-occlusive crises and potentially damaging organs over time.
Casgevy approaches the disease in a fundamentally different way.
Doctors collect a patient's own blood-forming stem cells and use CRISPR/Cas9 gene editing outside the body. The edited cells are then returned to the patient after conditioning treatment.
The goal is to enable the body to produce high levels of fetal hemoglobin, which helps prevent red blood cells from sickling.
When Casgevy first received U.S. approval for sickle cell disease in 2023, it was for patients age 12 and older.
On July 1, 2026, the FDA lowered that threshold to age two for eligible patients with recurrent vaso-occlusive crises.
The agency simultaneously expanded the treatment's approval for transfusion-dependent beta thalassemia to patients age two and older.
That matters because the damage caused by serious genetic blood disorders can accumulate over time.
Making a potentially transformative therapy available earlier in childhood creates the possibility of intervening much sooner in the course of disease.
But Casgevy is not an ordinary prescription.
Treatment involves collecting stem cells, chemotherapy-based conditioning and transplantation of the edited cells. It requires specialized centers and substantial medical support.
The breakthrough is real. So is the complexity of delivering it.